Search ResultsShowing Results for 'Heinz Reichmann'
The complement system in NMOSD and MG: A target for therapeutic benefit?
Watch specialists in neurological disorders share their insights on the role of complement and complement therapeutics in patients with neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG).
- Describe the role of complement in the pathophysiology of NMOSD and MG
- Evaluate markers of complement activation as diagnostic and prognostic biomarkers in NMOSD and MG
- Discuss recently approved and experimental inhibitors of the complement system for the treatment of NMOSD and MG
Heinz Reichmann, EAN 2020 – Unmet Needs in the Treatment of Parkinson’s
We were fortunate to have the opportunity to catch up with European editorial board member, Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany), who spoke to us about unmet needs in the treatment of Parkinson’s disease and clinical evidence supporting the efficacy and safety of catechol-O-methyltransferase inhibition as a means to prolong the effects of […]
Heinz Reichmann, EAN 2020 – OPTIPARK Study in Patients with Parkinson’s and Motor Fluctuations
Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany) shares key findings and expert insights into the OPTIPARK study, a prospective, open-label, uncontrolled, single-group, multi-centre trial in patients with Parkinson’s disease and wearing-off motor fluctuations (ClinicalTrials.gov Identifier: NCT02847442). Questions 1. What were the aims and design of the OPTIPARK study? (0:05) 2. What were the efficacy […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2022: Highlights in Parkinson’s disease
In an interview with touchNEUROLOGY, Prof. Heinz Reichmann (University of Dresden Medical School, Germany) gave us his insight into his highlights in Parkinson’s disease, the interventions currently under investigation and how he sees management strategies for Parkinson’s disease evolving in the coming years. Questions: What are your highlights from the Parkinson’s disease scientific sessions at […]
Heinz Reichmann, MDS 2020 – Gut Microbiome and Parkinson’s Disease
As always, we were pleased to have the opportunity to catch-up with valued editorial board member Heinz Reichmann (Technische Universität Dresden, Dresden, Germany), who spoke to us on the topic of the lecture he gave during the on-demand sessions entitled: The Gut Microbiome in the Pathogenesis of Parkinson’s Disease. Questions 1. Could you tell us […]
Professor Reichmann’s research interests include neuromuscular disorders, extrapyramidal movement disorders and neurosarcoidosis, disorders of energy metabolism in brain and muscle. He is affiliated with a number of organisations, including President of the European Neurological Society and a member of the following professional associations: the first Chairman of the German Society of Neurology, the second President […]
New Treatment Options for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare inherited childhood disease characterised by progressive muscle wasting. Affected children are unable to sit without support, or walk, and often require respiratory and nutritional support to live beyond 2 years of age.1 The disease occurs in approximately 1 in 10,000 live births and usually manifests in the first […]